Patents by Inventor Masoud Tavazoie
Masoud Tavazoie has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230338314Abstract: The invention features methods of treating disorders related to increased levels of myeloid derived suppressor cells such as cancer or infections. The disclosure also provides methods of treating cancer including combinations of LXR? agonists and immunotherapies such as PD1 inhibitors, PDL1 inhibitors, and adoptive T-cell transfer therapy.Type: ApplicationFiled: May 3, 2023Publication date: October 26, 2023Applicant: The Rockefeller UniversityInventors: Sohail Tavazoie, Masoud Tavazoie
-
Patent number: 11648220Abstract: The invention features methods of treating disorders related to increased levels of myeloid derived suppressor cells such as cancer or infections. The disclosure also provides methods of treating cancer including combinations of LXR? agonists and immunotherapies such as PD1 inhibitors, PDL1 inhibitors, and adoptive T-cell transfer therapy.Type: GrantFiled: January 11, 2017Date of Patent: May 16, 2023Assignee: The Rockefeller UniversityInventors: Sohail Tavazoie, Masoud Tavazoie
-
Publication number: 20230146646Abstract: The present disclosure provides antibody-drug conjugates comprising (i) antibodies that specifically bind to Mer Tyrosine Kinase (MERTK) (e.g., human MERTK, or both human and mouse MERTK), and (ii) cytotoxic agents conjugated directly to the antibodies or conjugated to the antibodies via linkers, and compositions comprising such antibody-drug conjugates, wherein the antibodies contained in the antibody-drug conjugates agonize MERTK signaling of endothelial cells. The present disclosure also provides methods for treating cancer, by administering an antibody-drug conjugate that comprises (i) an antibody that specifically binds to MERTK and agonizes MERTK signaling of endothelial cells, and (ii) a cytotoxic agent conjugated directly to the antibody or conjugated to the antibody via a linker.Type: ApplicationFiled: December 6, 2022Publication date: May 11, 2023Applicants: The Rockefeller University, Inspirna, Inc.Inventors: Sohail F. Tavazoie, Masoud Tavazoie, Nils Henrik Halberg
-
Patent number: 11613588Abstract: The present disclosure provides antibody-drug conjugates comprising (i) antibodies that specifically bind to Mer Tyrosin Kinase (MERTK) (e.g., human MERTK, or both human and mouse MERTK), and (ii) cytotoxic agents conjugated directly to the antibodies or conjugated to the antibodies via linkers, and compositions comprising such antibody-drug conjugates, wherein the antibodies contained in the antibody-drug conjugates agonize MERTK signaling of endothelial cells. The present disclosure also provides methods for treating cancer, by administering an antibody-drug conjugate that comprises (i) an antibody that specifically binds to MERTK and agonizes MERTK signaling of endothelial cells, and (ii) a cytotoxic agent conjugated directly to the antibody or conjugated to the antibody via a linker.Type: GrantFiled: June 26, 2018Date of Patent: March 28, 2023Assignee: The Rockefeller UniversityInventors: Sohail F. Tavazoie, Masoud Tavazoie, Nils Henrik Halberg
-
Publication number: 20220220222Abstract: The present disclosure provides antibodies (e.g., humanized antibodies) that specifically bind to Mer Tyrosine Kinase (MERTK; e.g., human MERTK) and compositions comprising such antibodies. The present disclosure also provides antibody-drug conjugates comprising (i) an anti-MERTK antibody or antigen-binding fragment thereof described herein that specifically binds to MERTK (e.g., human MERTK), and (ii) cytotoxic agents conjugated directly to the antibodies or conjugated to the antibodies via linkers, and compositions comprising such antibody-drug conjugates. The present disclosure also provides methods for treating cancer, comprising administering to a human subject in need thereof (a) an anti-MERTK antibody that specifically binds to MERTK (e.g., human MERTK) or an antigen-binding fragment thereof described herein, or (b) an antibody-drug conjugate that comprises (i) an anti-MERTK antibody or antigen-binding fragment thereof that specifically binds to MERTK (e.g.Type: ApplicationFiled: December 23, 2021Publication date: July 14, 2022Applicant: Inspirna, Inc.Inventors: Masoud Tavazoie, Isabel Kurth, Shugaku Takeda, Celia Andreu-Agullo, Ivo Lorenz
-
Publication number: 20220127680Abstract: This disclosure presents methods and reagents for cancer prognosis and treatment based on APOE genotyping. Specifically, the presence of the APOE2 genotype is indicative of a poor prognosis for the subject, whereas the presence of the APOE4 genotype is indicative of a good prognosis for the subject. The disclosed methods and reagents are useful for treating cancer and for making medical and clinical decisions on adjuvant therapy, tumor surveillance, and the likelihood of disease progression.Type: ApplicationFiled: February 28, 2020Publication date: April 28, 2022Applicant: The Rockefeller UniverstiyInventors: Sohail Tavazoie, Benjamin N. Ostendorf, Masoud Tavazoie, Foster Gonsalves
-
Patent number: 11242407Abstract: The present disclosure provides antibodies (e.g., humanized antibodies) that specifically bind to Mer Tyrosine Kinase (MERTK; e.g., human MERTK) and compositions comprising such antibodies. The present disclosure also provides antibody-drug conjugates comprising (i) an anti-MERTK antibody or antigen-binding fragment thereof described herein that specifically binds to MERTK (e.g., human MERTK), and (ii) cytotoxic agents conjugated directly to the antibodies or conjugated to the antibodies via linkers, and compositions comprising such antibody-drug conjugates. The present disclosure also provides methods for treating cancer, comprising administering to a human subject in need thereof (a) an anti-MERTK antibody that specifically binds to MERTK (e.g., human MERTK) or an antigen-binding fragment thereof described herein, or (b) an antibody-drug conjugate that comprises (i) an anti-MERTK antibody or antigen-binding fragment thereof that specifically binds to MERTK (e.g.Type: GrantFiled: February 25, 2020Date of Patent: February 8, 2022Assignee: Inspirna, Inc.Inventors: Masoud Tavazoie, Isabel Kurth, Shugaku Takeda, Celia Andreu-Agullo, Ivo Lorenz
-
Patent number: 11225524Abstract: The present disclosure provides antibodies that specifically bind to Mer Tyrosine Kinase (MERTK) (e.g., human MERTK, or both human and mouse MERTK) and compositions comprising such antibodies, wherein said antibody agonizes MERTK signaling on endothelial cells. The present disclosure also provides methods for treating cancer, by administering an antibody that specifically binds to MERTK and agonizes MERTK signaling on endothelial cells.Type: GrantFiled: January 24, 2019Date of Patent: January 18, 2022Assignee: The Rockefeller UniversityInventors: Sohail Tavazoie, Nils Halberg, Masoud Tavazoie
-
Publication number: 20200291135Abstract: The present disclosure provides antibodies (e.g., humanized antibodies) that specifically bind to Mer Tyrosine Kinase (MERTK; e.g., human MERTK) and compositions comprising such antibodies. The present disclosure also provides antibody-drug conjugates comprising (i) an anti-MERTK antibody or antigen-binding fragment thereof described herein that specifically binds to MERTK (e.g., human MERTK), and (ii) cytotoxic agents conjugated directly to the antibodies or conjugated to the antibodies via linkers, and compositions comprising such antibody-drug conjugates. The present disclosure also provides methods for treating cancer, comprising administering to a human subject in need thereof (a) an anti-MERTK antibody that specifically binds to MERTK (e.g., human MERTK) or an antigen-binding fragment thereof described herein, or (b) an antibody-drug conjugate that comprises (i) an anti-MERTK antibody or antigen-binding fragment thereof that specifically binds to MERTK (e.g.Type: ApplicationFiled: February 25, 2020Publication date: September 17, 2020Applicant: Rgenix, Inc.Inventors: Masoud Tavazoie, Isabel Kurth, Shugaku Takeda, Celia Andreu-Agullo, Ivo Lorenz
-
Publication number: 20200255543Abstract: The present disclosure provides antibody-drug conjugates comprising (i) antibodies that specifically bind to Mer Tyrosin Kinase (MERTK) (e.g., human MERTK, or both human and mouse MERTK), and (ii) cytotoxic agents conjugated directly to the antibodies or conjugated to the antibodies via linkers, and compositions comprising such antibody-drug conjugates, wherein the antibodies contained in the antibody-drug conjugates agonize MERTK signaling of endothelial cells. The present disclosure also provides methods for treating cancer, by administering an antibody-drug conjugate that comprises (i) an antibody that specifically binds to MERTK and agonizes MERTK signaling of endothelial cells, and (ii) a cytotoxic agent conjugated directly to the antibody or conjugated to the antibody via a linker.Type: ApplicationFiled: June 26, 2018Publication date: August 13, 2020Applicants: The Rockefeller University, Rgenix, Inc.Inventors: Sohail F. Tavazoie, Masoud Tavazoie
-
Publication number: 20190241676Abstract: The present disclosure provides antibodies that specifically bind to Mer Tyrosine Kinase (MERTK) (e.g., human MERTK, or both human and mouse MERTK) and compositions comprising such antibodies, wherein said antibody agonizes MERTK signaling on endothelial cells. The present disclosure also provides methods for treating cancer, by administering an antibody that specifically binds to MERTK and agonizes MERTK signaling on endothelial cells.Type: ApplicationFiled: January 24, 2019Publication date: August 8, 2019Applicant: The Rockefeller UniversityInventors: Sohail Tavazoie, Nils Halberg, Masoud Tavazoie
-
Patent number: 10221248Abstract: The present disclosure provides antibodies that specifically bind to Mer Tyrosine Kinase (MERTK) (e.g., human MERTK, or both human and mouse MERTK) and compositions comprising such antibodies, wherein said antibody agonizes MERTK signaling on endothelial cells. The present disclosure also provides methods for treating cancer, by administering an antibody that specifically binds to MERTK and agonizes MERTK signaling on endothelial cells.Type: GrantFiled: December 21, 2015Date of Patent: March 5, 2019Assignee: The Rockefeller UniversityInventors: Sohail Tavazoie, Nils Halberg, Masoud Tavazoie
-
Publication number: 20190029984Abstract: The invention features methods of treating disorders related to increased levels of myeloid derived suppressor cells such as cancer or infections. The disclosure also provides methods of treating cancer including combinations of LXR? agonists and immunotherapies such as PD1 inhibitors, PDL1 inhibitors, and adoptive T-cell transfer therapy.Type: ApplicationFiled: January 11, 2017Publication date: January 31, 2019Applicant: The Rockefeller UniversityInventors: Sohail Tavazoie, Masoud Tavazoie
-
Publication number: 20180002444Abstract: The present disclosure provides antibodies that specifically bind to Mer Tyrosine Kinase (MERTK) (e.g., human MERTK, or both human and mouse MERTK) and compositions comprising such antibodies, wherein said antibody agonizes MERTK signaling on endothelial cells. The present disclosure also provides methods for treating cancer, by administering an antibody that specifically binds to MERTK and agonizes MERTK signaling on endothelial cells.Type: ApplicationFiled: December 21, 2015Publication date: January 4, 2018Applicant: The Rockefeller UniversityInventors: Sohail Tavazoie, Nils Halberg, Masoud Tavazoie